methyl 3-carbamothioylbenzoate | 106748-27-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl 3-carbamothioylbenzoate
• 英文别名: 3-thiocarbamoyl-benzoic acid methyl ester
• CAS: 106748-27-0
• 化学式: C₉H₉NO₂S
• mdl: MFCD20233581
• 分子量: 195.242
• InChiKey: MBBRSLODSVCTGY-UHFFFAOYSA-N

物化性质

• 沸点：
  340.4±44.0 °C(Predicted)
• 密度：
  1.268±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.111
• 拓扑面积：
  84.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  methyl 3-carbamothioylbenzoate 在 Dowex 1x8 (chloride form) 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 26.0h， 生成 dimethyl 3-{3-[(4-phenyl)thiazol-2-yl]benzamido}propylsulfonium chloride
  参考文献：
  名称：

  Synthesis and properties of some novel anti-calmodulin drugs

  摘要：

  The preparation and properties of some novel inhibitors of calmodulin function are described. The compounds are cationic derivatives of phenyl-substituted thiazoles which inhibit the calmodulin stimulation of cyclic-AMP phosphodiesterase and are active against animal tumor cells in culture. These derivatives form the basis for the preparation of new, more potent inhibitors of calmodulin function which could take advantage of the reported elevated levels of calcium-bound calmodulin in tumor cells and show preferential anti-tumor activity. (C) 1999 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(99)00092-9
• 作为产物：
  描述：

  3-(氯羰基)苯甲酸甲酯 在 磷酸酐 、 ammonium hydroxide 、 硫化氢 、 二乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 生成 methyl 3-carbamothioylbenzoate
  参考文献：
  名称：

  Synthesis and properties of some novel anti-calmodulin drugs

  摘要：

  The preparation and properties of some novel inhibitors of calmodulin function are described. The compounds are cationic derivatives of phenyl-substituted thiazoles which inhibit the calmodulin stimulation of cyclic-AMP phosphodiesterase and are active against animal tumor cells in culture. These derivatives form the basis for the preparation of new, more potent inhibitors of calmodulin function which could take advantage of the reported elevated levels of calcium-bound calmodulin in tumor cells and show preferential anti-tumor activity. (C) 1999 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(99)00092-9

文献信息

• MEDICINAL COMPOSITIONS
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP1402900A1

  公开（公告）日：2004-03-31

  The present invention relates to an agent for the prophylaxis or treatment of pain, an agent for suppressing activation of osteoclast, and an inhibitor of osteoclast formation, which contains a p38 MAP kinase inhibitor and/or a TNF-α production inhibitor.

  本发明涉及一种用于预防或治疗疼痛的药剂，一种用于抑制破骨细胞活化的药剂，以及一种包含p38 MAP激酶抑制剂和/或TNF-α产生抑制剂的破骨细胞形成抑制剂。
• CONCOMITANT DRUGS
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP1354603A1

  公开（公告）日：2003-10-22

  The present invention relates to a pharmaceutical agent containing one or more kinds of a p38 MAP kinase inhibitor and/or a TNF-α production inhibitor and one or more kinds of drugs selected from the group consisting of (1) a non-steroidal antiinflammatory drug, (2) a disease-modifying anti-rheumatic drug, (3) an anti-cytokine drug, (4) an immunomodulator, (5) a steroid and (6) a c-Jun N-terminal kinase inhibitor in combination. This combination agent is useful as a prophylactic or therapeutic agent of the diseases such as rheumatism, arthritis and the like, and other diseases.

  本发明涉及一种含有一种或多种p38 MAP激酶抑制剂和/或TNF-α产生抑制剂以及从（1）非甾体抗炎药、（2）疾病修饰性抗风湿药、（3）抗细胞因子药物、（4）免疫调节剂、（5）类固醇和（6）c-Jun N末端激酶抑制剂中选择的一种或多种药物的药物制剂。这种组合药剂可用作预防或治疗风湿病、关节炎等疾病以及其他疾病的药物。
• [EN] EIF4E INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS D'EIF4E ET LEURS UTILISATIONS
  申请人：PIC THERAPEUTICS INC

  公开号：WO2021178488A1

  公开（公告）日：2021-09-10

  The present invention provides compounds inhibiting elF4E activity and compositions and methods of using thereof.

  本发明提供了抑制elF4E活性的化合物以及使用它们的组合物和方法。
• Cyclic derivatives as modulators of chemokine receptor activity
  申请人：Carter H. Percy

  公开号：US20050054627A1

  公开（公告）日：2005-03-10

  The present application describes modulators of MCP-1 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the treatment of rheumatoid arthritis, multiple sclerosis, atherosclerosis and asthma.

  当前申请描述了MCP-1的调节剂，其化学公式为(I):或其药用可接受的盐形式，用于治疗类风湿性关节炎、多发性硬化症、动脉粥样硬化和哮喘。
• Dihydro-benzo &lsqb;b&rsqb;&lsqb;1,4&rsqb;diazepin-2-one derivatives
  申请人：Hoffman-La Roche Inc.

  公开号：US06544985B2

  公开（公告）日：2003-04-08

  This invention is a dihydro-benzo[b][1,4]diazepin-2-one derivative of the formula wherein R1, R2, R3, X and Y are as defined in the specification. The invention includes pharmaceutical compositions containing these compounds, a process for their preparation, their use in preparation of pharmaceutical compositions and administration of an effective amount of the compounds for the treatment or prevention of acute and/or chronic neurological disorders to a patient in need of such treatment.

  这项发明是一种具有以下结构的二氢苯并[b][1,4]二氮杂环己酮衍生物的公式 其中R1、R2、R3、X和Y如规范中定义。该发明包括含有这些化合物的药物组合物，其制备方法，它们在制备药物组合物和向需要此类治疗的患者施用有效量的化合物以治疗或预防急性和/或慢性神经系统疾病的用途。